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Objectives: Untreated hepatitis C virus (HCV) infection results in chronic liver 
disease. The prevalence in The Netherlands is estimated at 0.1-0.4% with 50% of 
patients having HCV genotype 1 (GT1). Sofosbuvir (SOF), a novel Direct Antiviral 
Agent (DAA), reached high rates of sustained virological response (SVR) when 
given with pegylated interferon-α and ribavirin (PegIFN-α /RBV) in chronic HCV (all 
genotypes). This study compares the costs per successfully treated patient with 
sofosbuvir compared to current standard of care (SoC) in the Netherlands in treat-
ment-naïve GT1 patients. MethOds: A Markov transition cost-utility model was 
used, reflecting efficacy and safety data from published RCTs with SOF+PegIFN- 
α /RBV, PegIFN-α /RBV, telaprevir (TVR) +PegIFN-α /RBV and boceprevir (BOC) 
+PegIFN-α /RBV. Medical resource use is based on clinical guidelines and expert 
opinion. Costs include treatment costs, monitoring costs, costs for treatment of 
complications and adverse events. The model has a lifetime horizon and costs 
are discounted with 4% and outcomes with 1.5%. Successfully treated patients 
are defined as having an SVR. Results are presented for a treatment-naïve GT1 
population. Results: The SVR rate for SOF ranged from 91.7% in non-cirrhotic 
patients to 80.1% in cirrhotic patients. This was 43.6% and 23.6% for PegIFN-α , 75.4% 
and 61.9% in TVR and 64.1% and 55% for BOC. Total treatment costs ranged from 
€ 55,376 to € 70,336 for SOF (non-cirrhotic and cirrhotic), € 22,240 and € 44,751 for 
PegIFN-α , € 42,593 to € 60,071 for TVR and € 39,634 to € 57,647 for BOC. The costs per 
SVR varied from € 60.388 to € 87,050 for SOF (non-cirrhotic and cirrhotic), € 51,009 
to € 189,623 for PegIFN-α , € 56,489 to € 97,045 for TVR and € 61,832 to € 104,813 for 
BOC. cOnclusiOns: The costs per successfully treated patient with sofosbuvir are 
comparable to current standard of care in GT1 treatment naive patients without 
cirrhosis and are lower than SoC in cirrhotic patients in The Netherlands.
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Objectives: Typically, healthy adults are not targeted for influenza vaccination, 
leading to out-of-pocket expenses if they choose to be vaccinated. This can be a 
deterrent to vaccination coupled with a low concern for consequences of infec-
tion. However, despite a lower attack and complication rate than other age/risk 
groups, infection in healthy employees can result in important loss of productivity 
to employers. We estimated the benefits of vaccinating healthy employees with 
a quadrivalent inactivated influenza vaccine (QIV). MethOds: A decision tree 
model was developed to evaluate an annual employer-paid vaccination program 
for working adults in the UK versus no vaccination. Probabilities and costs were 
from peer-reviewed literature and government reports. A population of 5,000 
healthy employees, a 75% vaccination coverage and an average daily productivity 
of two times the average UK wage were assumed. Vaccine efficacy estimates were 
based on systematic reviews/meta-analyses and a 10-year history of match/mis-
match. Sensitivity analysis of uncertainty was conducted. Results: The model 
estimated that vaccination with QIV would avert 159 cases of influenza, and 
1,066 days of absenteeism, resulting in a productivity loss of £134,007 annually. 
Considering the vaccine and administration costs (£57,675) the employer would 
save £76,332. The results are highly sensitive to the number of days an employee is 
absent due to a simple infection (no hospitalisation), the attack rate, and average 
productivity. In scenario analysis if the average productivity is set simply to the 
average wage, the employer would still save £9,328. cOnclusiOns: Vaccination 
campaigns paid for by an employer are estimated to be cost saving when infection 
results in at least 1.7 days of absenteeism for each case. A higher mortality rate 
(due to a more virulent strain, and/or inclusion of at risk adults) would introduce 
replacement costs, thereby raising the cost saving to the employer if they under-
took a vaccination program.
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Objectives: Fidaxomicin is the first in a new class of macrocylic antibiotics, 
indicated for the treatment of adults with Clostridium difficile infection (CDI) also 
known as C. difficile-associated diarrhoea (CDAD). Two phase III comparative clinical 
studies showed that fidaxomicin was non-inferior to vancomycin for clinical cure, 
and superior for recurrence and sustained clinical cure. The study objective was to 
perform a cost-effectiveness analysis of fidaxomicin for the treatment of severe 
CDI and the first severe recurrence compared to oral vancomycin from a Swedish 
health care perspective. MethOds: A Markov model was developed to analyse 
the cost-effectiveness of fidaxomicin compared to vancomycin in the treatment of 
patients with severe CDI, and patients with initial severe CDI recurrences, respec-
tively. The patient enters the model in the CDI health state and is treated either 
with fidaxomicin or vancomycin. Each treatment cycle was 10 days and the total 
time horizon was one-year. Deterministic and probabilistic sensitivity analyses 
were performed. Health state utilities were derived from the literature. Results: 
Fidaxomicin was associated with an increased cost per patient in the severe CDI 
population and was cost-saving in severe recurrent CDI patients. A utility gain was 
demonstrated in both fidaxomicin patient populations. The ICER was SEK 83,159 
per QALY for severe CDI and dominant for patients with a severe CDI recurrence 
(ICER = SEK -92,738 per QALY). Sensitivity analyses found the results to be robust. 
(1 EURO = 9.07 SEK). cOnclusiOns: Fidaxomicin was cost-effective in severe CDI 
Objectives: Although the real-time PCR-based assay SeptiFast® has proven 
its utility in different clinical settings, limited data are still available on its eco-
nomic performance. An Italian two-center observational study was conducted on 
hematological patients with signs of SIRS-SS (Systemic Inflammatory Response 
Syndrome with Suspected Sepsis) in order to partially fill this information 
gap. MethOds: 138 retrospective cases of SIRS-SS managed by classical diag-
nostic procedure are compared to prospectively collected data of 137 episodes 
managed with the addition of PCR assay. Events were paired through propensity-
score matching (PSM), based on a set of covariates identified by a backward selec-
tion algorithm, under two levels of tolerance for score difference: standard caliper 
(1) and a more restrictive threshold (0.05). SIRS-SS related mortality represents 
the primary clinical outcome; as secondary outcome, average LOSE (Length Of 
SIRS Episode) is considered. Costs, including diagnostic assays and pharmaceu-
tical charges, were recorded and compared between cohorts. Results: A total 
of 101 pairs of highly matched SIRS-SS episodes have been formed. Prospective 
cohort shows a non-significant trend to a lower mortality (8.24% vs. 13.48%). Under 
more stringent matching condition (77 pairs), episodes experienced by prospective 
patients are associated to a significantly lower mortality (3.13% vs 14.71%). No 
significant differences in the average LOSE are recorded. Traditional diagnostic 
assays cost is € 152 lower in the prospective cohor; however, this saving is com-
pletely offset by the cost of the PCR assay. The greatest saving related to the use 
of PCR assay is linked to the hard reduction in the empirical therapy (€ 488.44 per 
episode), main driver of the overall saving (€ 430.73 per episode), which results 
statistically significant. cOnclusiOns: These findings suggest that the routine 
use of combined traditional and PCR diagnostic assays may conduct to an early 
saving of broad-spectrum antibiotics, money, and health.
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Objectives: Human papillomavirus (HPV) vaccines offer primary prevention 
of HPV-related pre-cancers and cancers. AS04-adjuvanted HPV-16/18 vaccine 
(AS04v) has shown high efficacy (efficacy irrespective of the HPV type) in cervi-
cal high grade lesions (CIN2+, CIN3+). The objective of this study is to estimate 
overall impact on cervical cancer (CC) burden expected from AS04v in the Iberian 
Peninsula (Spain and Portugal). MethOds: Potential decline in CC cases resulting 
from women vaccination with AS04v was estimated using a previously published 
model. Model outcomes considered were estimated based on number of CC cases 
avoided associated with HPV specific CC incidence (HPV-16/18 cases and irrespec-
tive of HPV type). Vaccine effectiveness (VE, end-of-study analysis HPV-008 trial) 
against HPV-16/18 was set at 100% weighted with HPV-16/18 incidence reported in 
CC in Spain & Portugal. VE irrespective of HPV type was set at 93%. Vaccination cov-
erage was varied from 0% to 100%. Incremental number of cases avoided HPV-16/18 
related and irrespective of HPV type were calculated. Potential costs avoided were 
also estimated based on published lifetime CC costs. Results: Through vaccina-
tion considering VE irrespective of type and 70% vaccination coverage, AS04v could 
avoid an additional 206 CC cases in Portugal and 626 CC cases in Spain compared 
with 412 and 1.009 cases, respectively, due to 16/18 HPV types. VE against non-
vaccine types increased the estimated potential number of CC cases prevented by 
33% and 38% in Portugal and Spain, respectively. Associated cost avoided due to 
reduced CC treatment could reach 1.536.644€ in Portugal and 6.374.865€ in Spain 
(33% and 38% due to overall efficacy respectively). Cases avoided may increase 
linearly with increasing vaccination coverage. cOnclusiOns: HPV vaccination 
could considerably contribute to reducing the burden of cervical cancer in Spain 
and Portugal. AS04v offers potential broad protection and could maximize disease 
burden reduction due to non-vaccine type VE.
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Objectives: To analyze cost effectiveness of dolutegravir when compared to ralte-
gravir in both treatment-naïve (TN) and treatment-experienced (TE) patients in 
Slovenia. MethOds: We adapted ARAMIS-DTG, a published micro-simulation 
decision model, to the real-life conditions in Slovenia by using locally-specific pop-
ulation data and treatment costs of HIV patients, who are currently predominantly 
receiving first-line treatment. In the model, individual patients were followed 
throughout their lifetime and transitioned through mutually exclusive health 
states with the probability of disease progression being continuously adjusted on 
individual patient characteristics and the occurrence of events such as virological 
failure, opportunistic infections and/or adverse events. We compared dolutegravir 
and raltegravir under a »price parity« scenario. Results: Our model has shown 
that more than 90% of life-time treatment costs of HIV patients in Slovenia were 
due to anti-retroviral drugs. Survival curves and CD4+ cell count indicated that 
treatment with dolutegravir was more effective than treatment with raltegravir in 
both TN and TE HIV patients. In TN patients, dolutegravir also reduced costs and 
thus dominated raltegravir (saved € 1,608 and gained 0.092 QALYs - discounted at a 
rate of 3.5%). In TE patients, the resulting ICER was € 23,382 per QALY with the cost 
increase being associated with an expected greater survival of patients treated 
with dolutegravir. When accounting for that factor then also in the TE group, 
dolutegravir dominated raltegravir. The sensitivity analysis showed robustness of 
findings in both groups of patients. cOnclusiOns: Results of our study indicate 
that the introduction of new integrase inhibitor dolutegravir in Slovenia would 
not only reduce the costs but also improve health outcomes of HIV treatment in 
both TN and TE patients.
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comycin in the treatment of adult CDI patients. The analysis focused on three 
CDI patient subgroups: cancer, concomitant antimicrobials, and renal impaired 
patients. MethOds: A Markov model was developed with a cycle length of 10 
days and a one year time horizon. The patient enters the model in the CDI health 
state and is treated with fidaxomicin, or vancomycin for 10 days. Health state 
utilities were derived from the literature. The model perspective was the Spanish 
health care provider. Deterministic and probabilistic sensitivity analyses were 
performed. Results: In all three CDI patient subgroups, fidaxomicin was domi-
nant compared to vancomycin. For cancer fidaxomicin resulted in cost savings of 
€ 2,397 with an incremental QALY gain of 0.016. For concomitant antibiotics fidax-
omicin resulted in cost savings of € 1,452 with an incremental QALY gain of 0.014. 
For renally impaired, fidaxomicin resulted in cost savings of € 1,432 and an incre-
mental QALY gain of 0.013. The main cost-effectiveness drivers were the recur-
rence rate and length of hospital stay. The probability of fidaxomicin being cost 
effective at the € 30,000 threshold was 96%, 94% and 96% respectively for cancer, 
concomitant antimicrobials and renal impairment, respectively. cOnclusiOns: 
Fidaxomicin was dominant compared to vancomycin for these adult CDI patient 
subgroups.
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Objectives: We aimed at estimating the impact of extending the French influ-
enza vaccination programme from at-risk/elderly (≥ 65 years) only, to additionally 
include children (2-17 years). MethOds: A deterministic, age-structured, dynamic 
transmission model was used to simulate the transmission of influenza in the 
French population, under the current coverage with the trivalent inactivated vac-
cine (TIV) in at-risk/elderly individuals (= reference strategy) or after extending 
the coverage to healthy 2-17 years-old children with an intranasal, quadrivalent 
live-attenuated influenza vaccine (QLAIV) (= evaluated strategy). The transmis-
sion probabilities were determined using between-individuals contact patterns 
(“Polymod” matrix). Epidemiological, medical resources and costs data were issued 
by crossing data from literature and French resource-based value scales. The basic 
reproduction number (R0) of the model was calibrated to the observed numbers 
of influenza-like illness visits/year and deaths/year. The 10-year, undiscounted, 
number of symptomatic cases of confirmed influenza and direct medical costs 
(All-payer) were calculated for the 0-17 (direct effect) and ≥ 18 years-old (indirect 
effect). The incremental cost-effectiveness ratio (ICER) was calculated for the total 
population, using a 4% discount/year. Univariate and probabilistic sensitivity anal-
yses were performed. Results: Model calibration yielded R0= 1.27 (assuming 2.3 
million visits/year and 1,960 deaths/year). In the 0-17 years-old with 50% QLAIV 
coverage, the average number of confirmed influenza cases dropped by 865,000/
year, averting 58.4% of the cases occurring in the reference strategy and leading 
to 10-year savings of € 374 million. In the ≥ 18 years-old with unchanged TIV cover-
age, 1.2 million cases/year of confirmed influenza were averted (-27.6%), yielding 
additional 10-year savings of € 457 million. On average, 613 flu-related deaths were 
avoided annually. The ICER was € 18,000/life-year gained. The evaluated strategy 
was 98% cost-effective at a € 30,000/life-year gained threshold. cOnclusiOns: The 
model demonstrated the direct and indirect benefits of protecting healthy children 
against influenza with QLAIV, on public health and economic outcomes in France.
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Objectives: Multidrug-resistant tuberculosis (MDR-TB) is designated an orphan 
disease in Germany, where about ~65 patients are infected with multidrug-
resistant tuberculosis (MDR-TB). Regimens consisting of several drugs for up to 
24 months are the current standard of care (SoC) for treatment of MDR-TB. The 
aim of this analysis is to evaluate the costs and effectiveness of adding bedaqui-
line (BDQ) to a background regimen (BR) of the SoC in a German health care 
context. MethOds: A cohort based Markov model was used to estimate cost-
effectiveness of bedaquiline plus background regimen (BDQ+BR) vs. BR alone for 
treatment of MDR- and XDR-TB (extensively drug resistant). The effectiveness 
of treatment was evaluated in QALYs, DALYs and life year gained (LYG). Inputs 
into the model were derived from a bedaquiline randomised, placebo controlled 
trial and from published literature. Drug costs (in 2014 euros) were taken from 
the German drug directory; a yearly discount rate of 3% was applied and a time 
horizon of 10 years was assumed. Sensitivity analyses were performed to evalu-
ate the impact of model parameters. Results: For a base-case analysis with a 
cohort of 65 MDR-TB patients, adding bedaquiline to BR results in higher costs 
compared to BR alone (4,5 vs. 2,4 MM € ), but yields better outcomes (66 QALYs 
gained). The incremental cost per QALY gained (ICER) was calculated as 33.357 
€ . For a cohort exclusively of XDR-TB patients, the ICER was calculated as 17.915 
€ . To evaluate the impact of model parameters, further sensitivity analyses were 
performed. cOnclusiOns: Adding bedaquiline to a background regimen of anti-
TB drugs is cost-effective, probably even cost saving for patients with MDR- and 
XDR-TB, when compared to BR alone under different cost scenarios. Over a ten 
year period, cost savings were mostly achieved by lesser time of hospitalisation, 
although BDQ+BR drug costs are higher than BR alone.
and dominant in patients with a severe CDI recurrence from a Swedish health 
care perspective.
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seCoNd lINe treatmeNt reGImeNs for susPeCted methICIllIN-
resIstaNt staPhyloCoCCus aureus NosoComIal PNeumoNIa
Patel D.1, Niederman M.S.2, Li J.Z.3, Mcnamara R.4, Haider S.5, Stephens J.6
1Pharmerit North America LLC, Bethesda, MD, USA, 2Winthrop-University Hospital, Mineola, NY, 
USA, 3Pfizer, Inc., San Diego, CA, USA, 4Pfizer Inc, Collegeville, PA, USA, 5Pfizer Inc, Groton, CT, 
USA, 6Pharmerit International, Bethesda, MD, USA
Objectives: Appropriate and timely empiric treatment is very essential for methi-
cillin-resistant Staphylococcus aureus (MRSA) -related infections. Inadequate empiric 
treatment is associated with increased mortality and longer hospital stay. This study 
compares economic impact of initial empiric linezolid (Emp-LIN) vs. vancomycin 
(Emp-VAN) vs. no empiric MRSA coverage (NE-MRSA) before culture-confirmed 
treatment, for suspected MRSA nosocomial pneumonia (NP). MethOds: A 4 week 
decision model was developed capturing empiric, 1st and 2nd line therapy. Published 
literature and expert opinion provided clinical and resource use data, including 
efficacy, incremental mortality for NE-MRSA, adverse events, and length of hospital/
ICU stay. Cost and health utilities data were obtained from published literature. 
Base-case analysis used 2-day empiric, 10-day 1st/2nd-line treatment duration, 30% 
MRSA rate, and 1st line linezolid for NE-MRSA after culture confirmation. Patients 
with a negative culture for MRSA exited the model after empiric treatment, and 
were assigned a fixed cost for remaining treatment. Univariate and probabilistic 
sensitivity analyses were conducted. Costs were reported in 2014 USD. Results: 
Emp-LIN was associated with lower total costs ($41,975 vs. $42,288), and marginally 
greater QALY gain and overall treatment success compared to Emp-VAN, resulting in 
Emp-LIN ‘dominating’ Emp-VAN. Compared to NE-MRSA, Emp-LIN was more costly 
by $1,626, but had greater QALY gain (+0.836) and incremental treatment success 
(+5.9%), resulting in an incremental cost effectiveness ratio (ICER) of $1,946 per 
QALY gain, and $27,750 per successfully treated patient. Days in ICU stay, clinical 
efficacy, and MRSA rate had the greatest impact on ICER. Probability of Emp-LIN 
being cost-effective was 61% (vs. Emp-VAN) and 99% (vs. NE-MRSA) assuming a 
willingness-to-pay (WTP) of $50,000 per successfully treated patients and QALY gain 
respectively. cOnclusiOns: Early treatment with Emp-LIN is a cost-effective alter-
native to Emp-VAN and NE-MRSA at reasonable WTP threshold, and should be con-
sidered a preferred treatment choice, especially at hospitals with high MRSA rate.
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Objectives: Italian recommendations for human papillomavirus (HPV) immuni-
zation programmes currently target females only. However, males can be vectors 
in virus transmission and are at risk of disease infection. The BEST II study was 
designed to evaluate the cost-effectiveness (CE) of different interventions target-
ing females as well as males, and the economic impact of vaccination on a wide 
range of HPV-induced diseases. MethOds: A dynamic Bayesian Markov model 
was developed to investigate HPV transmission between sexual partners and the 
cost-effectiveness of several HPV vaccination strategies. Both sexes were included 
in a universal vaccination programme which was compared to screening-only 
and female-only vaccination. A range of HPV-induced diseases was considered 
(cervical, vaginal, vulvar, anal, head/neck and penile cancer, the associated pre-
cancerous stages as well as anogenital warts). The process of sexual mixing was 
estimated based on age-, gender- and sexual behavioural-specific factors to esti-
mate the force of infection dynamically. The degree of susceptibility to the virus, 
associated with early sexual debut, high number of partners, smoking and previ-
ous STIs, was also included. We considered several scenarios; the baseline assumes 
universal vaccination to be implemented for 12-year-old females and males. The 
follow-up period was 55 years. Results: According to our preliminary analysis, 
universal vaccination resulted as a cost-effective alternative when compared to 
screening-only (with an incremental CE ratio, ICER, of € 1,200) and to female-only 
vaccination (ICER = € 6,900). We performed extensive sensitivity analyses to para-
metric assumptions, which confirmed the good CE profile of universal vaccination 
in Italy. cOnclusiOns: Universal HPV vaccination of male and female cohorts is 
cost-effective compared to cervical screening and female-only vaccination, when 
accounting for a great variety of HPV-related diseases. This is mainly due to the 
fact that universal vaccination increases the effects of herd immunity and pro-
vides indirect protection against HPV.
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Objectives: Fidaxomicin is the first in a new class of macrocylic antibiotics, 
indicated in adults for the treatment of Clostridium difficile infections (CDI). The 
objective was to analyse the cost-utility of fidaxomicin compared to oral van-
